Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

What this Trial Is About

This research aims to evaluate the use of the sedative medication dexmedetomidine in the urgent treatment of patients experiencing recurrent ventricular arrhythmias, known as electrical storm (ES). ES is a serious condition characterized by three or more episodes of ventricular arrhythmias within 24 hours, posing a high risk of death both short- and long-term. The study is a multi-center, double-blinded, placebo-controlled, randomized trial designed to determine whether early sedation with dexmedetomidine provides meaningful benefits during acute treatment in intensive care units. Participants will be randomly assigned to receive either dexmedetomidine or a placebo (normal saline) upon admission to the intensive care unit. Those receiving dexmedetomidine will start at a dose of 0.3 mcg/kg/hr, titrated up to a target of 1.0 mcg/kg/hr or their maximum tolerated dose. Treatment will continue for 48 hours with a subsequent weaning phase determined by the treating physician. Placebo recipients will follow a similar dosing and weaning schedule using normal saline programmed as dexmedetomidine on the infusion pump. Throughout the study, participants will be closely monitored during their hospital stay, which averages about two weeks. Researchers will assess outcomes such as in-hospital death, ventricular arrhythmias requiring treatment, cardiac arrest, kidney failure, need for mechanical support, and length of intensive care and hospital stays. The primary outcome combines death or arrhythmia events during hospitalization after starting the study drug. Safety and treatment effects will be evaluated through these clinical measures and continuous monitoring during the acute care period.

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm